Specific bonding of puromycin to full-length protein at the C-terminus

被引:65
|
作者
Miyamoto-Sato, E
Nemoto, N
Kobayashi, K
Yanagawa, H
机构
[1] Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 1948511, Japan
[2] Yokohama Natl Univ, Fac Engn, Dept Chem & Biotechnol, Hodogaya Ku, Yokohama, Kanagawa 2408501, Japan
关键词
D O I
10.1093/nar/28.5.1176
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Puromycin, an analog of the 3' end of aminoacyl-tRNA, causes premature termination of translation by being linked non-specifically to growing polypeptide chains, Here we report the interesting phenomenon that puromycin acting as a non-inhibitor at very low concentration (e.g, 0.04 mu M) can bond only to full-length protein at the C-terminus, This was proved by using a carboxypeptidase digestion assay of the products obtained by Escherichia coli cell-free translation of: human tau 4 repeat (tau4R) mRNA in the presence of low concentrations of puromycin or its derivatives. The tau4R mRNA was modified to code for three C-terminal methionines, which were radioactively labeled, followed by a stop codon. The translation products could not be digested by carboxypeptidase if puromycin or a derivative was present at the C-terminus of full-length tau4R. Puromycin and its derivatives at 0.04-1.0 mu M bonded to 7-21% of full-length tau4R, depending on the ability to act as acceptor substrates. Furthermore, the bonding efficiency of a puromycin derivative to tau4R was decreased by addition of release factors. These results suggest that puromycin and its derivatives at concentrations lower than those able to compete effectively with aminoacyl-tRNA can bond specifically to full-length protein at a stop codon. This specific bonding of puromycin to full-length protein should be useful for in vitro selection of proteins and for in vitro and in vivo C-terminal end protein labeling.
引用
收藏
页码:1176 / 1182
页数:7
相关论文
共 50 条
  • [41] Genomic full-length sequence of the HLA-A*11:97 allele, identified by full-length group-specific sequencing
    Hu, Bin
    Jiao, Shuxian
    Chi, Xiaoyun
    Pang, Shutao
    HLA, 2020, 96 (05) : 625 - 626
  • [42] Genomic full-length sequence of the HLA-A*24:233 allele, identified by full-length group-specific sequencing
    Hu, Bin
    Jiao, Shuxian
    An, Run
    Pang, Shutao
    HLA, 2021, 97 (04) : 356 - +
  • [43] Refolding of the full-length non-structural protein 3 of hepatitis C virus
    Poliakov, A
    Danielson, UH
    PROTEIN EXPRESSION AND PURIFICATION, 2005, 41 (02) : 298 - 305
  • [44] Genomic full-length sequence of HLA-B*40:54 was identified by full-length group-specific sequencing
    Chen, Peng
    Xu, Yunping
    HLA, 2019, 93 (06) : 487 - +
  • [45] The genomic full-length sequence of the HLA-A*03:30 allele, identified by full-length group-specific sequencing
    Chi, Xiaoyun
    Fang, Ruifeng
    Jiao, Shuxian
    Hu, Bin
    Pang, Shutao
    HLA, 2021, 98 (05) : 469 - 471
  • [46] Genomic full-length sequence of HLA-B*15:178 was identified by full-length group-specific sequencing
    He, L-M.
    Yang, H.
    Xu, Y-P.
    Hong, W-X.
    HLA, 2018, 92 (04) : 246 - 248
  • [47] Genomic full-length sequence of the HLA-A*02:406 allele was identified by full-length group-specific sequencing
    An, Run
    Hu, Bin
    Jiao, Shuxian
    Pang, Shutao
    HLA, 2022, 100 (03) : 256 - 258
  • [48] Genomic full-length sequence of the HLA-C*03:227 allele was identified by full length group-specific sequencing
    Feng, Zhihui
    An, Run
    Jiao, Shuxian
    Pang, Shutao
    HLA, 2022, 100 (01) : 79 - 81
  • [49] Genomic full-length sequence of the HLA-A*26:89 allele was identified by full-length group-specific sequencing
    An, Run
    Jiao, Shuxian
    Chi, Xiaoyun
    Pang, Shutao
    HLA, 2021, 97 (03) : 222 - 224
  • [50] Genomic full-length sequence of HLA-B*50:31 was identified by full-length group-specific sequencing
    Chen, Peng
    Xu, Yunping
    HLA, 2019, 93 (06) : 493 - 495